Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Homo sapiens

We report RNAseq gene expression data following ARS-1620 treatment and shKRAS expressing cells (NCI-H358). We also compare gene expression changes following treatment with ARS-1620 or trametinib in NCI-H358, LU65 (KRAS-G12C+), and A549 (KRAS-G12S+) cells. Additionally we report a time course (4, 24, 48hr) of ARS-1620 and trametinib treated NCI-H358 cells. Overall design: Examination of whole transcriptome RNAseq data from 3 separate experimental designs: 1. H358 cells, treated with ARS-1620 & DMSO (24hr) and transduced with shRNA control & KRAS (24hr post infection), 2. H358, LU65, and A549 cells treated with DMSO, ARS-1620, or trametinib (for 24hr), and 3. H358 cells treated as time course of ARS-1620 (1uM) or trametinib (50nM)